Success Metrics

Clinical Success Rate
78.8%

Based on 26 completed trials

Completion Rate
79%(26/33)
Active Trials
0(0%)
Results Posted
23%(6 trials)
Terminated
7(21%)

Phase Distribution

Ph phase_3
1
3%
Ph phase_1
20
61%
Ph phase_2
12
36%

Phase Distribution

20

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution33 total trials
Phase 1Safety & dosage
20(60.6%)
Phase 2Efficacy & side effects
12(36.4%)
Phase 3Large-scale testing
1(3.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.8%

26 of 33 finished

Non-Completion Rate

21.2%

7 ended early

Currently Active

0

trials recruiting

Total Trials

33

all time

Status Distribution
Completed(26)
Terminated(7)

Detailed Status

Completed26
Terminated7

Development Timeline

Analytics

Development Status

Total Trials
33
Active
0
Success Rate
78.8%
Most Advanced
Phase 3

Trials by Phase

Phase 120 (60.6%)
Phase 212 (36.4%)
Phase 31 (3.0%)

Trials by Status

terminated721%
completed2679%

Recent Activity

0 active trials
Showing 5 of 33
completedphase_2

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00118092
completedphase_2

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

NCT00118248
terminatedphase_2

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

NCT00096109
completedphase_2

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

NCT00514371
completedphase_1

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

NCT00773344
View all 33 trials

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT00118092Phase 2

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Completed
NCT00118248Phase 2

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Completed
NCT00096109Phase 2

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

Terminated
NCT00514371Phase 2

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

Completed
NCT00773344Phase 1

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Completed
NCT00779428Phase 2

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Completed
NCT00577889Phase 2

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer

Completed
NCT00121264Phase 1

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed
NCT00058253Phase 1

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed
NCT00117988Phase 2

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

Completed
NCT00093496Phase 2

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Completed
NCT00096005Phase 1

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Terminated
NCT00019708Phase 1

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated
NCT00098423Phase 1

Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

Completed
NCT00100997Phase 1

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Completed
NCT00104897Phase 2

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma

Completed
NCT00003969Phase 1

Geldanamycin Analogue in Treating Patients With Advanced Cancer

Completed
NCT00093405Phase 2

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer

Completed
NCT00004065Phase 1

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Completed
NCT00079404Phase 1

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
33